Bioatla, Inc. Stock Price, News & Analysis

BioAtla (NASDAQ: BCAB) announced clinical data for its AXL-targeting ADC mecbotamab vedotin (BA3011) will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, Nov 5-9, 2025, at National Harbor, MD.

The presentation by Dr. Mihaela Druta on Nov 7, 2025 reports a median overall survival (OS) of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma (abstract #523). Poster session timing to be announced; slides will be posted in the company Publication section after the presentation.

BioAtla (NASDAQ:BCAB) has received FDA alignment on the Phase 3 trial design for ozuriftamab vedotin (Oz-V) in treating Oropharyngeal Squamous Cell Carcinoma (OPSCC). The trial will involve approximately 300 patients randomized between Oz-V and investigator's choice of standard treatments.

The company's Phase 2 trial demonstrated promising results with an overall response rate of 45% and median overall survival of 11.6 months, significantly outperforming current treatments which show only 0-3.4% response rates and 4.4 months median survival. The Phase 3 study design includes potential for accelerated approval based on response rate improvements, with full approval contingent on overall survival benefits.

BioAtla plans to initiate the Phase 3 study with a strategic partner in early 2026 and maintains guidance for completing a strategic partnership for one of its advanced clinical assets this year.

BioAtla (NASDAQ:BCAB) reported Q2 2025 financial results and clinical progress updates. The company's Phase 1 CAB-EpCAM x CAB-CD3 bispecific T-cell engager (BA3182) showed promising results with seven patients achieving tumor size reductions ranging from -5% to -25%. Their Fast Track Designated ozuriftamab vedotin (Oz-V) demonstrated strong efficacy in HPV+ head and neck cancer with a 45% overall response rate and 100% disease control rate.

Financial results showed R&D expenses decreased to $13.7M from $16.2M year-over-year, while net loss improved to $18.7M from $21.1M. The company ended Q2 with $18.2M in cash, down from $49.0M at 2024 year-end, and expects decreased quarterly cash burn as Phase 2 trials conclude. BioAtla remains confident in closing at least one partnership transaction in 2025.

BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Q2 2025 earnings conference call for August 7, 2025, at 4:30 p.m. ET.

The company will discuss financial results for the quarter ended June 30, 2025, and provide business updates. The earnings release will be available on the company's website before the call. Investors can access the call through the provided domestic and international dial-in numbers or via webcast.

BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company, will present at the 2025 ESMO TAT Asia Meeting in Hong Kong from July 18-20, 2025. The company will deliver an oral presentation about their first-in-human phase I study of BA3182, a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager for treating refractory metastatic adenocarcinoma.

The presentation will be given by Jennifer B. Brooke Valerin on July 18, 2025 at 15:59-16:06 GMT+8. The presentation materials will be available on BioAtla's website after the event.

BioAtla (NASDAQ:BCAB) presented promising first-in-human data for BA3182, their dual-conditionally binding EpCAM x CD3 bispecific T-cell engager, at the 2025 ESMO Gastrointestinal Cancers Congress. The ongoing Phase 1 trial included 39 heavily pretreated patients with metastatic adenocarcinoma, receiving doses ranging from 0.0026 mg to 0.6 mg weekly.

Key findings showed five patients achieved objective tumor size reductions ranging from -8% to -25%, with two colorectal carcinoma patients showing prolonged progression-free intervals of 11 and 14 months. Adverse events were generally low-grade and manageable, with subcutaneous dosing showing an improved plasma profile compared to intravenous administration. The trial continues dose escalation at 1.2 mg weekly, with updated Phase 1 data expected in 2H2025.

BioAtla (NASDAQ: BCAB) presented promising Phase 2 clinical trial data for Ozuriftamab Vedotin (Oz-V) in treating HPV-associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC). The trial showed a 45% overall response rate and 100% disease control rate in patients treated with 1.8 mg/kg Q2W dosing. Key results include median duration of response of 9.9 months, progression-free survival of 4.7 months, and ongoing overall survival of 11.6 months. This significantly outperforms current standard treatments, which only achieve a 3.4% response rate. The drug demonstrated a favorable safety profile, with mostly low-grade adverse events and only 15% of patients experiencing grade ≥3 related adverse events. With Fast Track Designation from the FDA, BioAtla plans to finalize Phase 3 trial design, targeting potential accelerated approval for this underserved patient population.

BioAtla (NASDAQ: BCAB) reported its Q1 2025 financial results and clinical progress. Key highlights include: CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 study has dosed first three patients at 300 micrograms, with data expected mid-2025. Mecbotamab vedotin showed exceptional 2-year survival rate of 59% in mKRAS non-small cell lung cancer, significantly outperforming standard care's typical <20% rate. Ozuriftamab vedotin demonstrated strong results in HPV+ head and neck cancer with 100% disease control rate and 45% overall response rate. Financially, R&D expenses decreased to $12.4M from $18.9M YoY, while net loss improved to $15.3M from $23.2M. Cash position stands at $32.4M as of March 31, 2025, expected to fund operations through key clinical readouts in 1H 2026.

BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced its upcoming participation in the Citizens Life Sciences Conference in New York. The company, which specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, will deliver a corporate update and engage in one-on-one investor meetings.

The presentation is scheduled for Wednesday, May 7, 2025, at 10:00 a.m. ET in New York. Company management will be available for individual investor discussions during the two-day conference, which runs from May 7-8, 2025. A webcast link has been provided for those interested in following the corporate update remotely.